April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Early Intravitreal Bevacizumab for Central Retinal Vein Occlusion
Author Affiliations & Notes
  • V. Daien
    Ophthalmolgy, CHU MONTPELLIER, Chu montpellier, France
  • C. Schneider
    Ophthalmolgy,
    Chu Montpellier, Chu Montpellier, France
  • S. Navarre
    Ophthalmolgy,
    Chu Montpellier, Chu Montpellier, France
  • D. Audemard
    Ophthalmolgy, Chu Nimes, Chu Nimes, France
  • I. Aubry
    Ophthalmolgy, Clinique Beau Soleil, Montpellier, France
  • P. Fesler
    Internal Medicine,
    Chu Montpellier, Chu Montpellier, France
  • M. Villain
    Ophthalmolgy,
    Chu Montpellier, Chu Montpellier, France
  • Footnotes
    Commercial Relationships  V. Daien, None; C. Schneider, None; S. Navarre, None; D. Audemard, None; I. Aubry, None; P. Fesler, None; M. Villain, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2803. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. Daien, C. Schneider, S. Navarre, D. Audemard, I. Aubry, P. Fesler, M. Villain; Early Intravitreal Bevacizumab for Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2803.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of 3 intravitreal bevacizumab (Avastin, Genentech) injections on visual acuity and foveal retinal thickness at early stage of central retinal vein occlusion (CRVO) at 6 months after the beginning of treatment.

Methods: : This prospective, noncomparative, consecutive, interventional case series included 14 patients (14 eyes) with a recent central retinal vein occlusion (less than 3 months) associated with macular edema and initial visual acuity worse than 20/40. Early Treatment Diabetic Retinopathy Study Best-Corrected Visual Acuity (BCVA), ophthalmic examination, and Optical Coherence Tomography (OCT) were performed at baseline and during every follow-up visits. All patients received 3 intravitreal injections of bevacizumab (1.25 mg) each separated by 4 weeks between the injections. Study endpoints were BVCA and central macular edema 3 months after the last injection.

Results: : Results (mean +/- sd, median +/- range) : Mean age was 65 +/-11 and median duration of symptoms before the first injection was 30 days (20-60 days). Mean visual acuity improved significantly from 0,78 +/-0,42 logMAR at baseline to 0,61 +/-0,55 logMAR (P = 0.05) at the last visit. For the group of subject with initial visual acuity betwen 20/50 to 20/200 54,5 % improved, 36,4% stayed at the same level and 9,1 % got worse. When initial visual acuity was worse than 20/200, the prognosis for vision was poor, 67 % remained at this level and 33 % improved. Mean central retinal thickness decreased significantly from 563 +/- 200 µm at baseline to 328+/- 134 µm (P < 0.002) during the last visit (3 months after last injection).

Conclusions: : Intravitreal bevacizumab injections given in the first 3 months after onset of central retinal vein occlusion may result in a significant increase in vision and a concomitant decrease in macular oedema. We did not observe any short-term adverse effects during our study. A prospective randomized and controlled trial with a longer follow up is necessary to confirm these results.

Keywords: vascular occlusion/vascular occlusive disease • macula/fovea • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×